Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Amends Year-End Financial Guidance to Reflect Tekmira Payout

Premium

Alnylam Pharmaceuticals this week updated its financial guidance to include the impact of its payout to Tekmira Pharmaceuticals as part of the companies' litigation settlement deal.

As reported by Gene Silencing News, this week the companies announced that they had settled their longstanding legal battle. As part of the deal, Alnylam agreed to pay Tekmira $65 million now and $10 million in milestones expected for 2013.

Previously this month, Alnylam had said it expected to end 2012 with more than $280 million in cash, cash equivalents, and marketable securities (GSN 11/8/2012).

With the settlement, however, Alnylam said this week that it will take a $65 million charge in the fourth quarter, and it now expects its year-end cash position to be more than $215 million.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.